For patients with NSCLC in the earlier stages (AJCC stages I‐II), a high CD147 level was associated with unsatisfactory clinical outcomes, whereas a high CD147‐K148me2 level worked for NSCLC patients in the advanced stages (AJCC stages III‐IV) (Figure 1G,H; Figure S3G,H, Supporting Information). This evidence concerns the gene BSG and non-small cell lung carcinoma.